FUNDUSCEIN-25
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUNDUSCEIN-25 is a small-molecule injectable diagnostic agent approved in 1976 by Novartis. The specific indication and mechanism of action are not documented in available data, but the injectable route and diagnostic classification suggest ophthalmic or vascular imaging use. This is a legacy product nearing loss of exclusivity.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked job opportunities, this brand faces significant contraction and offers limited career growth potential.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FUNDUSCEIN-25 offers limited career advancement due to zero linked job openings and approaching loss of exclusivity. This role is best suited for professionals managing legacy products or seeking stability in a maintenance-phase brand rather than growth opportunities.
Brand ManagerField Sales Representative
Worked on FUNDUSCEIN-25 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.